Immatics N.V. (IMTX)

10.14 -0.12 (-1.17%) As of 01:03PM EDT. Market open.

Immatics N.V.

Paul-Ehrlich-Strasse 15
Tübingen 72076
Germany
49 7071 5397 0
https://www.immatics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 432

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Harpreet Singh Ph.D.	CEO, MD, Member of Management Board & Executive Director	884.44k	N/A	1975
Dr. Toni Weinschenk Ph.D.	Co-Founder & Chief Innovation Officer	N/A	N/A	1974
Mr. Arnd Christ MBA	Chief Financial Officer	N/A	N/A	1966
Mr. Steffen Walter Ph.D.	Chief Operations Officer	N/A	N/A	1977
Mr. Edward A. Sturchio J.D.	General Counsel & Secretary	N/A	N/A	1976
Dr. Carsten Reinhardt M.D., Ph.D.	Chief Development Officer	N/A	N/A	1967
Mr. Cedrik M. Britten M.D.	Chief Medical Officer	N/A	N/A	1976
Mr. Jordan Silverstein	Head of Strategy	N/A	N/A	1980
Dr. Hans-Georg Rammensee Ph.D.	Co-Founder & Member of the Scientific Advisory Board	N/A	N/A	N/A
Mr. Ephraim Hofsäß M.Sc.	Vice President of SEC Reporting & Accounting	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Corporate governance

Immatics N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.